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Wilson disease (WD, OMIM# 277900) is a rare inborn error of copper accumulation inherited 
in an autosomal recessive manner. It is caused by mutations in the copper transporting P-
type ATPase gene (ATP7B) (Thomas GR et al., 1995a). The disease is manifested at a 
median age of 12 to 23 years as hepatolenticular degeneration resulting from accumulation of 
copper primarily in the liver and brain. Patients mostly present with hepatic, neuropsychiatric 
or mixed symptoms (Das SK and Ray K, 2006). Varied clinical and biochemical 
manifestations often complicate diagnostic workup and diagnosis can be challenging 
especially for patients who are asymptomatic or present with liver disease. Failure to 
diagnose WD before its substantial progression is the leading cause of morbidity and 
mortality. But if patients can be diagnosed early enough, lifelong de-coppering with 
appropriate chelating agents can lead to gradual improvement and make them largely 
symptom free for the rest of their lives (Walshe JM, 2007). There is no single clinical or 
biochemical test to exclude WD. Genetic analysis still remains to be the confirmatory 
approach to detect the disease especially in sporadic cases with no family history and 
ambiguous clinical indications. 
When the work for this dissertation was initiated, several studies have revealed the 
ATP7B mutation spectrum from North Indian (Kumar S et al., 2005), South Indian (Santhosh 
S et al., 2006) and East Indian (Gupta A et al., 2005, 2007a) (our group) WD population. 
However, the WD mutation pattern from West India was yet to be elucidated. Hence, the 
genetic, clinical and functional studies leading to this dissertation have sequentially focussed 
on the following areas (i) further characterization of molecular defects present in ATP7B gene 
in East Indian WD patients and exploration of the ATP7B mutation spectrum from West India 
(ii) screening of the ATP7B regulatory region in patients with single detectable coding 
mutations or lack of any, and followed it up with functional characterization of variants in the 
promoter and 5'UTR, (iii) Investigating the genotype-phenotype relationships in WD by 
generating a matrix for exploration of the clinico-genetic interface, followed by evaluation of 
candidate modifier loci, and (iv) functional evaluation of variants detected in the ATP7B 
coding region by localization and trafficking studies. 
A total of 199 WD patients (174 East Indian and 25 West Indian) mostly with 
neurological problems from 178 unrelated families comprising of 687 individuals have been 
included in this study prospectively. This group is an extension of a previous study from our 
lab where 25 East Indian patients had been characterized with both ATP7B mutations and 
single mutations found in a few (Gupta et al., 2007a). ATP7B mutation screening has been 
undertaken in 174 patients (East Indian: 149, West Indian: 25). Finally, a comprehensive 
mutation profile of all 199 patients is described. In this study, we detected 29 reported and 22 
novel mutations after screening most of the ATP7B coding region (exons 2 to 21) and flanking 
intron-exon boundaries. Of the reported ones, 19 defects had been reported from other 
populations but detected for the first time in our patient cohort and 10 variants were previously 
described by our group (Gupta A et al., 2007a) in addition to finding those during the study 
related to my dissertation. Adding up all mutations, our patient cohort harbors a total of 10 
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common and 48 rare lesions in the coding region of ATP7B. Three mutations (p.G1061E, 
p.N1270S and p.A1049A-fs) are shared between East and West. The common mutations 
have been found to account for 74% of characterized mutant alleles with p.C271X (63/260) 
and p.G1101R (7/31) being the most prevalent in East and West Indian patient cohorts, 
respectively. Comparison of mutation pools across India suggested that the exons 2, 8, 9, 13, 
14, 15, 18 and Intron 4 harbor the prevalent mutations and should be screened with priority in 
the Indian WD population. In addition to the mutations, 28 innocuous variants could be 
detected during this study. Mutations in both the alleles could be characterized in 114 
patients, while in 63 patients only one mutation could be detected in the coding region. No 
coding mutations could be detected in 22 patients. Further studies on these patients with 
missing mutation(s) are described in relevant sections below. 
WD is one of the few genetic diseases, the progression of which can be controlled if 
diagnosed early enough. Knowledge of common mutations in a population would pave the 
way for rapid diagnosis, even in some suspect case without family information, before the 
manifestation of overt clinical symptoms. But mutation screening is a time consuming 
process. So, a parallel strategy was employed to identify the carriers and presymptomatic 
individuals in 41 East Indian and 19 West Indian WD affected families with multiple sibs to 
provide relevant information faster without waiting for determination of the underlying causal 
mutation. By studying the inheritance of linked polymorphic microsatellite markers D13S314 
and D13S316 in the affected pedigrees, we could detect 5 presymptomatic, 40 carrier and 36 
normal individuals. Mutation information, when available was utilized to resolve the 
ambiguous cases. 
Most genetic studies reported earlier focussed on studying the ATP7B coding region 
but the gene promoter, though characterized, remained largely unexplored. As already 
described, 85 patients (63 + 22) in our pool could not be characterized for either one or both 
ATP7B mutations even after screening much of the coding region. In order to identify the 
missing mutations, we screened the ATP7B promoter and both the 5'- and 3'-UTRs in these 
patients. We detected 5 novel and 6 reported variants in the promoter and 5'UTR. Promoter 
cloning, site-directed mutagenesis and dual luciferase assay was carried out for functional 
evaluation of these variants. Five variants and one haplotype in the 5' regulatory region could 
be implicated in WD pathogenesis based on significant down regulation of the promoter 
activity. We carried out segregation studies in pedigrees to dissect the phase of alleles with 
respect to promoter variants and downstream coding mutations. We further hypothesized that 
ATP7B promoter variations altering its activity might also be present in patients where both 
coding mutations have been detected and influence the expression of the mutated protein. 
The differences in promoter strengths could have the potential to add on to the observed 
clinical heterogeneity in addition to the influence of other confounding genetic and 
environmental factors. Thus, the role of promoter variants in the regulation of ATP7B merits 
further investigation. 
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Till date, no nucleotide substitutions in the ATP7B 3'UTR have been associated with 
WD phenotype. This study reports 3 novel variations in this region in WD patients, however, 
further experiments are required to ascertain their status as mutations or rare innocuous 
variants. We reached a mutation detection frequency of 77% in our study. 
We devised a Neurological Involvement Score (NIS) to explore the spectrum of 
neurological association across cognition, behaviour and motor domains in WD patients with 
preferential neuropsychiatric manifestation. The scale was found to have high internal 
consistency (Cronbach’s α 0.802) and inter-rater reliability (ICC 0.888). Thus NIS was highly 
reproducible. Subsequently we undertook a novel unified approach of genotype-phenotype 
(G2P) correlation by utilizing NIS as a simple tool to explore the neuropsychiatric arena of WD 
patients in light of the mutations identified across different ATP7B protein domains. Using age 
at onset and neurological involvement score, we generated a G2P matrix. The scheme of 
G2P matrix provided opportunities to examine and compare the patient phenotypes with 
respect to same genotype and also across different protein domains. We observed that the 
truncation mutations could be equally deleterious irrespective of the site of termination being 
early or late in the polypeptide chain. Compound heterozygotes bearing combination of 
missense and truncation mutations indicated missense mutations to retain more functionality 
in the mutated protein as reported previously (Nicastro E et al., 2009). Specific mutations in 
the nucleotide binding domain were found to attribute hepatic predominance. 
Patients with same/similar mutation background would be expected to have similar 
presentation. The most interesting observation was made when we encountered a few 
patients who depicted stark difference in their clinical manifestation as compared to other 
patients in the same mutation cluster. We counted the patients with divergent phenotypes as 
“outliers” in the matrix. Possible roles of COMMD1 and ATOX1, two genes in copper 
homeostasis pathway, were also investigated for their potential to act as modifier loci in the 
outliers, though no variant could be implicated for the cause. Since the ‘basal level 
heterogeneity’ of presenting symptoms in WD is not exclusively explained by the ATP7B 
mutations, and cases of misdiagnosis and phenotypic overlap have been reported implicating 
additional genes such as NPC1, SLC33A1, and SLC30A10 (Connemann BJ et al., 2012; 
Huppke P et al., 2012a; Quadri M et al., 2012), we propose that these loci should be studied 
for their putative role in imparting WD features by some novel pathophysiological 
mechanisms. 
The diagnostic delay emerged to be a confounding factor for G2P analysis. The mean 
diagnostic delay in our study was 19.5 months (0.2 to 180 months) and there is opportunity 
for further improvement. 
Missense mutations might have a spectrum of consequences on the mutant protein. 
In this context, we made an attempt to explore the effect of missense mutations on cellular 
localization and anterograde trafficking of ATP7B. GFP fusion constructs for 9 different 
ATP7B mutants selected from different domains were investigated for their localization and 
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copper responsive redistribution. While 6 of 9 mutants showed normal behavior, 2 mutants 
(p.G1061E and p.G1101R) were found to be grossly mislocalized to endoplasmic reticulum 
while 1 mutant (p.S1362A) was found to be unresponsive to copper induction. Mutations 
might affect several properties of ATP7B which could alter its precise conformation, catalytic 
and kinase mediated phosphorylation, ATPase activity, copper binding and transport rate 
across membranes etc. Each of these factors might have deleterious consequences on 
normal copper distribution and may lead to WD. Thus, a detailed functional exploration of the 
effect of missense variants on other properties of the protein would provide deeper insight of 
their effect on the clinical phenotype of the patients. 
The studies leading to this dissertation have resulted in the following publication as 
noted below and additional manuscript describing unpublished work is under preparation: 
Mukherjee S, Dutta S, Majumdar S, Biswas T, Jaiswal P, Sengupta M, Bhattacharya A, 
Gangopadhyay PK, Bavdekar A, Das SK, Ray K. Genetic defects in Indian Wilson disease 
patients and genotype-phenotype correlation. Parkinsonism and Related Disorders 2013; (In 
press); DOI, 10.1016/j.parkreldis.2013.09.021 
